Novigenix
runs an AI-powered blood-transcriptomic platform with published results on early colorectal-cancer detection, and recently secured funding (EUR 1.8 million) to scale its precision-oncology platform and spun out an AI-focused unit to accelerate its immune-intelligence technology.
- Country
- Switzerland
Growth
AI blood-transcriptomic platform
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Multi-cancer early detection (MCED) | diagnostics-medtech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.